Local drug makers brace for severe damage

Korea's drug makers are bracing for a prolonged downdraft in the domestic pharmaceutical market following the government's ex post facto drug pricing inspection on 4,300 items from 190 medical institutions, which have been conducted by the Health Insurance Review Agency in a period ranging from April 9 to May 24 this year.

Many manufacturers has confronted a serious roadblock posed by the go...